Upexi (UPXI) Competitors $3.87 +0.08 (+2.11%) (As of 12/26/2024 05:30 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends UPXI vs. CARM, SYBX, APRE, MEIP, SPRB, FLGC, PRPH, HCWB, NERV, and BTAIShould you be buying Upexi stock or one of its competitors? The main competitors of Upexi include Carisma Therapeutics (CARM), Synlogic (SYBX), Aprea Therapeutics (APRE), MEI Pharma (MEIP), Spruce Biosciences (SPRB), Flora Growth (FLGC), ProPhase Labs (PRPH), HCW Biologics (HCWB), Minerva Neurosciences (NERV), and BioXcel Therapeutics (BTAI). These companies are all part of the "pharmaceutical products" industry. Upexi vs. Carisma Therapeutics Synlogic Aprea Therapeutics MEI Pharma Spruce Biosciences Flora Growth ProPhase Labs HCW Biologics Minerva Neurosciences BioXcel Therapeutics Carisma Therapeutics (NASDAQ:CARM) and Upexi (NASDAQ:UPXI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, community ranking, media sentiment, earnings, dividends and profitability. Which has higher valuation and earnings, CARM or UPXI? Upexi has higher revenue and earnings than Carisma Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCarisma Therapeutics$20.27M0.91-$86.88M-$1.56-0.28Upexi$22.08M0.18-$16.93MN/AN/A Is CARM or UPXI more profitable? Upexi has a net margin of -28.34% compared to Carisma Therapeutics' net margin of -314.78%. Upexi's return on equity of -54.97% beat Carisma Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Carisma Therapeutics-314.78% -957.20% -96.39% Upexi -28.34%-54.97%-23.24% Which has more volatility & risk, CARM or UPXI? Carisma Therapeutics has a beta of 1.44, meaning that its stock price is 44% more volatile than the S&P 500. Comparatively, Upexi has a beta of 0.04, meaning that its stock price is 96% less volatile than the S&P 500. Does the MarketBeat Community favor CARM or UPXI? Carisma Therapeutics received 13 more outperform votes than Upexi when rated by MarketBeat users. Likewise, 76.19% of users gave Carisma Therapeutics an outperform vote while only 42.86% of users gave Upexi an outperform vote. CompanyUnderperformOutperformCarisma TherapeuticsOutperform Votes1676.19% Underperform Votes523.81% UpexiOutperform Votes342.86% Underperform Votes457.14% Do insiders and institutionals hold more shares of CARM or UPXI? 44.3% of Carisma Therapeutics shares are owned by institutional investors. Comparatively, 5.7% of Upexi shares are owned by institutional investors. 12.6% of Carisma Therapeutics shares are owned by company insiders. Comparatively, 38.3% of Upexi shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts rate CARM or UPXI? Carisma Therapeutics presently has a consensus target price of $4.94, suggesting a potential upside of 1,017.65%. Upexi has a consensus target price of $25.00, suggesting a potential upside of 545.99%. Given Carisma Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Carisma Therapeutics is more favorable than Upexi.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Carisma Therapeutics 0 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.43Upexi 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media refer more to CARM or UPXI? In the previous week, Carisma Therapeutics and Carisma Therapeutics both had 2 articles in the media. Carisma Therapeutics' average media sentiment score of 1.87 beat Upexi's score of -0.09 indicating that Carisma Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Carisma Therapeutics Very Positive Upexi Neutral SummaryCarisma Therapeutics beats Upexi on 10 of the 16 factors compared between the two stocks. Ad WealthPressYour chance to get on the next “60-Second Trade”Ever heard of the “60-Second Trade”? It’s a unique cash flow strategy that lets regular traders target anywhere from $100 to a couple of thousand in extra cash flow in as little as 7 days… In on Monday, out on Friday!Just head over here! Get Upexi News Delivered to You Automatically Sign up to receive the latest news and ratings for UPXI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UPXI vs. The Competition Export to ExcelMetricUpexiMedicinals & botanicals IndustryBusiness SectorNASDAQ ExchangeMarket Cap$4.03M$1.14B$7.32B$9.26BDividend YieldN/AN/A2.27%4.26%P/E RatioN/A31.7328.5017.33Price / Sales0.186.30411.39123.75Price / CashN/A10.6631.4037.83Price / Book0.121.926.135.06Net Income-$16.93M-$50.37M$125.09M$225.13M7 Day Performance-12.44%1.76%5.92%4.21%1 Month Performance-16.59%-8.71%10.92%3.06%1 Year Performance-81.92%-6.43%20.13%17.91% Upexi Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UPXIUpexi1.887 of 5 stars$3.87+2.1%$25.00+546.0%-81.6%$4.03M$22.08M0.00130Short Interest ↑CARMCarisma Therapeutics3.941 of 5 stars$0.39-7.2%$4.94+1,173.2%-85.7%$16.20M$20.27M-0.2520Positive NewsSYBXSynlogic1.0258 of 5 stars$1.38-2.7%N/A-63.6%$16.17M$3.37M-0.336Short Interest ↑Negative NewsAPREAprea Therapeutics3.5956 of 5 stars$2.90-4.9%$15.50+434.5%-7.7%$15.76M$580,000.00-1.037Short Interest ↑Gap DownMEIPMEI Pharma4.0336 of 5 stars$2.36-5.6%$7.00+196.6%-61.3%$15.73M$65.30M-0.34100Analyst ForecastShort Interest ↓High Trading VolumeSPRBSpruce Biosciences3.8007 of 5 stars$0.38-5.6%$3.90+933.1%-82.6%$15.59M$7.10M-0.4020Short Interest ↑FLGCFlora Growth1.9057 of 5 stars$1.06+1.0%$5.00+371.7%-18.4%$15.29M$64.15M0.00280Short Interest ↑Gap DownPRPHProPhase Labs3.3473 of 5 stars$0.63+3.8%$11.00+1,636.1%-86.8%$15.13M$12.75M-0.50130Short Interest ↓HCWBHCW Biologics0.3546 of 5 stars$0.40-11.2%N/A-63.0%$15.08M$3.50M-0.4040Short Interest ↑Gap DownNERVMinerva Neurosciences3.9619 of 5 stars$2.12-1.9%$5.00+135.8%-64.3%$14.83MN/A-4.829Short Interest ↓High Trading VolumeBTAIBioXcel Therapeutics4.5342 of 5 stars$0.35+1.6%$5.00+1,343.4%-87.7%$14.81M$2.28M-0.1690Short Interest ↑Positive News Related Companies and Tools Related Companies CARM Alternatives SYBX Alternatives APRE Alternatives MEIP Alternatives SPRB Alternatives FLGC Alternatives PRPH Alternatives HCWB Alternatives NERV Alternatives BTAI Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:UPXI) was last updated on 12/27/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Upexi, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Upexi With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
